| nivolumab versus standard treatment | |||
| Checkmate-141, 2016 NCT02105636 | nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks versus standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). | patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy | open-label |
| pembrolizumab versus standard treatment | |||
| KEYNOTE-040, NCT02252042 | pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle versus standard treatment (methotrexate, docetaxel or cetuximab) | patients with recurrent or metastatic head and neck squamous cell cancer | open-design |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
